Centessa Pharmaceuticals plc Stock

Centessa Pharmaceuticals Limited, formerly Centessa Pharmaceuticals plc, is a clinical-stage pharmaceutical company, developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness, impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It has an early-stage immuno-oncology program focused on its LockBody technology platform. The OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1, NT2 and idiopathic hypersomnia. ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.